{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:22:20Z","timestamp":1793323340631,"version":"4.5.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T00:00:00Z","timestamp":1540252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T00:00:00Z","timestamp":1540252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s11914-018-0491-3","type":"journal-article","created":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T05:21:55Z","timestamp":1540272115000},"page":"712-723","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Updates in CKD-Associated Osteoporosis"],"prefix":"10.1007","volume":"16","author":[{"given":"Pascale","family":"Khairallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas L.","family":"Nickolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,23]]},"reference":[{"key":"491_CR1","doi-asserted-by":"crossref","unstructured":"Bikbov B, Perico N, Remuzzi G, on behalf of the GBDGDEG. Disparities in chronic kidney disease prevalence among males and females in 195 countries: analysis of the Global Burden of Disease 2016 Study. Nephron. 2018:1\u20136.","DOI":"10.1159\/000489897"},{"key":"491_CR2","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1046\/j.1523-1755.2000.00178.x","volume":"58","author":"AM Alem","year":"2000","unstructured":"Alem AM, Sherrard DJ, Gillen DL, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 2000;58:396\u20139.","journal-title":"Kidney Int"},{"key":"491_CR3","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1002\/jbmr.2862","volume":"31","author":"SM Kim","year":"2016","unstructured":"Kim SM, Long J, Montez-Rath M, Leonard M, Chertow GM. Hip fracture in patients with non-dialysis-requiring chronic kidney disease. J Bone Miner Res Off J Am Soc Bone Miner Res. 2016;31:1803\u20139.","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res."},{"key":"491_CR4","first-page":"569","volume":"94","author":"NIH Consensus Development Panel on Osteoporosis Prevention","year":"2001","unstructured":"NIH Consensus Development Panel on Osteoporosis Prevention. Diagnosis, and Therapy, March 7-29, 2000: highlights of the conference. South Med J. 2001;94:569\u201373.","journal-title":"South Med J"},{"key":"491_CR5","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1681\/ASN.2009121208","volume":"21","author":"TL Nickolas","year":"2010","unstructured":"Nickolas TL, Stein E, Cohen A, et al. Bone mass and microarchitecture in CKD patients with fracture. J Am Soc Nephrol. 2010;21:1371\u201380.","journal-title":"J Am Soc Nephrol"},{"key":"491_CR6","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s00198-003-1435-y","volume":"14","author":"S Klawansky","year":"2003","unstructured":"Klawansky S, Komaroff E, Cavanaugh PF Jr, et al. Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int. 2003;14:570\u20136.","journal-title":"Osteoporos Int"},{"key":"491_CR7","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1159\/000489671","volume":"47","author":"AK Sharma","year":"2018","unstructured":"Sharma AK, Toussaint ND, Masterson R, et al. Deterioration of cortical bone microarchitecture: critical component of renal osteodystrophy evaluation. Am J Nephrol. 2018;47:376\u201384.","journal-title":"Am J Nephrol"},{"key":"491_CR8","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1002\/jbmr.309","volume":"26","author":"HH Malluche","year":"2011","unstructured":"\u2022 Malluche HH, Mawad HW, Monier-Faugere MC. Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res. 2011;26:1368\u201376 This paper defined the characteristics of renal osteodystrophy in the contemporary era, in light of the marked differences that have occurred over the past several decades in the management of CKD-MBD.","journal-title":"J Bone Miner Res"},{"key":"491_CR9","doi-asserted-by":"crossref","unstructured":"Carvalho C, Magalhaes J, Neto R, et al. Cortical bone analysis in a predialysis population: a comparison with a dialysis population. J Bone Miner Metab. 2016.","DOI":"10.1007\/s00774-016-0781-8"},{"key":"491_CR10","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1002\/jbmr.1916","volume":"28","author":"TL Nickolas","year":"2013","unstructured":"Nickolas TL, Stein EM, Dworakowski E, et al. Rapid cortical bone loss in patients with chronic kidney disease. J Bone Miner Res. 2013;28:1811\u201320.","journal-title":"J Bone Miner Res"},{"key":"491_CR11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S8756-3282(00)00434-8","volume":"28","author":"D Vashishth","year":"2001","unstructured":"Vashishth D, Gibson GJ, Khoury JI, Schaffler MB, Kimura J, Fyhrie DP. Influence of nonenzymatic glycation on biomechanical properties of cortical bone. Bone. 2001;28:195\u2013201.","journal-title":"Bone"},{"key":"491_CR12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11914-017-0366-z","volume":"15","author":"EMB McNerny","year":"2017","unstructured":"McNerny EMB, Nickolas TL. Bone quality in chronic kidney disease: definitions and diagnostics. Curr Osteoporos Rep. 2017;15:207\u201313.","journal-title":"Curr Osteoporos Rep."},{"key":"491_CR13","doi-asserted-by":"publisher","first-page":"146","DOI":"10.2215\/CJN.05940611","volume":"7","author":"K Wesseling-Perry","year":"2012","unstructured":"Wesseling-Perry K, Pereira RC, Tseng CH, et al. Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin J Am Soc Nephrol. 2012;7:146\u201352.","journal-title":"Clin J Am Soc Nephrol."},{"key":"491_CR14","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.kint.2015.12.004","volume":"89","author":"TB Drueke","year":"2016","unstructured":"Drueke TB, Massy ZA. Changing bone patterns with progression of chronic kidney disease. Kidney Int. 2016;89:289\u2013302.","journal-title":"Kidney Int"},{"key":"491_CR15","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.kint.2016.12.029","volume":"91","author":"FG Graciolli","year":"2017","unstructured":"Graciolli FG, Neves KR, Barreto F, et al. The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease. Kidney Int. 2017;91:1436\u201346.","journal-title":"Kidney Int"},{"key":"491_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1093\/ndt\/gfu291","volume":"30","author":"SL Barker","year":"2015","unstructured":"Barker SL, Pastor J, Carranza D, et al. The demonstration of alphaKlotho deficiency in human chronic kidney disease with a novel synthetic antibody. Nephrol Dial Transplant. 2015;30:223\u201333.","journal-title":"Nephrol Dial Transplant."},{"key":"491_CR17","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1096\/fj.08-114397","volume":"23","author":"T Nakatani","year":"2009","unstructured":"Nakatani T, Sarraj B, Ohnishi M, et al. In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23) -mediated regulation of systemic phosphate homeostasis. FASEB J. 2009;23:433\u201341.","journal-title":"FASEB J."},{"key":"491_CR18","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.bone.2017.02.006","volume":"100","author":"J Kaludjerovic","year":"2017","unstructured":"Kaludjerovic J, Komaba H, Lanske B. Effects of klotho deletion from bone during chronic kidney disease. Bone. 2017;100:50\u20135.","journal-title":"Bone"},{"key":"491_CR19","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.kint.2017.02.014","volume":"92","author":"H Komaba","year":"2017","unstructured":"Komaba H, Kaludjerovic J, Hu DZ, et al. Klotho expression in osteocytes regulates bone metabolism and controls bone formation. Kidney Int. 2017;92:599\u2013611.","journal-title":"Kidney Int"},{"key":"491_CR20","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1359\/jbmr.080220","volume":"23","author":"H Wang","year":"2008","unstructured":"Wang H, Yoshiko Y, Yamamoto R, et al. Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res Off J Am. Soc Bone Miner Res. 2008;23:939\u201348.","journal-title":"J Bone Miner Res Off J Am. Soc Bone Miner Res."},{"key":"491_CR21","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1159\/000368940","volume":"39","author":"OM Akchurin","year":"2015","unstructured":"Akchurin OM, Kaskel F. Update on inflammation in chronic kidney disease. Blood Purif. 2015;39:84\u201392.","journal-title":"Blood Purif"},{"key":"491_CR22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00223-013-9749-z","volume":"93","author":"M Rossini","year":"2013","unstructured":"Rossini M, Gatti D, Adami S. Involvement of WNT\/beta-catenin signaling in the treatment of osteoporosis. Calcif Tissue Int. 2013;93:121\u201332.","journal-title":"Calcif Tissue Int"},{"key":"491_CR23","doi-asserted-by":"publisher","first-page":"19883","DOI":"10.1074\/jbc.M413274200","volume":"280","author":"X Li","year":"2005","unstructured":"Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005;280:19883\u20137.","journal-title":"J Biol Chem"},{"key":"491_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025900","volume":"6","author":"AR Wijenayaka","year":"2011","unstructured":"Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One. 2011;6:e25900.","journal-title":"PLoS One"},{"key":"491_CR25","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3899\/jrheum.100089","volume":"38","author":"SY Wang","year":"2011","unstructured":"Wang SY, Liu YY, Ye H, et al. Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis. J Rheumatol. 2011;38:821\u20137.","journal-title":"J Rheumatol"},{"key":"491_CR26","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.2215\/CJN.03500412","volume":"7","author":"J Gupta","year":"2012","unstructured":"Gupta J, Mitra N, Kanetsky PA, et al. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol. 2012;7:1938\u201346.","journal-title":"Clin J Am Soc Nephrol."},{"key":"491_CR27","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1136\/ard.2010.132852","volume":"69","author":"GR Heiland","year":"2010","unstructured":"Heiland GR, Zwerina K, Baum W, et al. Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis. 2010;69:2152\u20139.","journal-title":"Ann Rheum Dis"},{"key":"491_CR28","doi-asserted-by":"publisher","first-page":"877","DOI":"10.2215\/CJN.06550810","volume":"6","author":"D Cejka","year":"2011","unstructured":"Cejka D, Herberth J, Branscum AJ, et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol. 2011;6:877\u201382.","journal-title":"Clin J Am Soc Nephrol"},{"key":"491_CR29","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1002\/jbmr.1630","volume":"27","author":"Y Sabbagh","year":"2012","unstructured":"Sabbagh Y, Graciolli FG, O'Brien S, et al. Repression of osteocyte Wnt\/beta-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res. 2012;27:1757\u201372.","journal-title":"J Bone Miner Res"},{"key":"491_CR30","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/ki.2013.547","volume":"86","author":"KL Naylor","year":"2014","unstructured":"Naylor KL, McArthur E, Leslie WD, et al. The three-year incidence of fracture in chronic kidney disease. Kidney Int. 2014;86:810\u20138.","journal-title":"Kidney Int"},{"key":"491_CR31","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1681\/ASN.2005111194","volume":"17","author":"TL Nickolas","year":"2006","unstructured":"Nickolas TL, McMahon DJ, Shane E. Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol. 2006;17:3223\u201332.","journal-title":"J Am Soc Nephrol."},{"key":"491_CR32","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S0272-6386(04)00958-8","volume":"44","author":"A Mittalhenkle","year":"2004","unstructured":"Mittalhenkle A, Gillen DL, Stehman-Breen CO. Increased risk of mortality associated with hip fracture in the dialysis population. Am J Kidney Dis. 2004;44:672\u20139.","journal-title":"Am J Kidney Dis."},{"key":"491_CR33","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","volume":"69","author":"S Moe","year":"2006","unstructured":"Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69:1945\u201353.","journal-title":"Kidney Int"},{"key":"491_CR34","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1093\/ndt\/gfg116","volume":"18","author":"GB Spasovski","year":"2003","unstructured":"Spasovski GB, Bervoets AR, Behets GJ, et al. Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis. Nephrol Dial Transplant. 2003;18:1159\u201366.","journal-title":"Nephrol Dial Transplant."},{"key":"491_CR35","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1359\/jbmr.090735","volume":"25","author":"C Tomiyama","year":"2010","unstructured":"Tomiyama C, Carvalho AB, Higa A, Jorgetti V, Draibe SA, Canziani ME. Coronary calcification is associated with lower bone formation rate in CKD patients not yet in dialysis treatment. J Bone Miner Res Off J Am Soc Bone Miner Res. 2010;25:499\u2013504.","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res."},{"key":"491_CR36","doi-asserted-by":"publisher","first-page":"296","DOI":"10.5414\/CNP70296","volume":"70","author":"G Lehmann","year":"2008","unstructured":"Lehmann G, Ott U, Kaemmerer D, Schuetze J, Wolf G. Bone histomorphometry and biochemical markers of bone turnover in patients with chronic kidney disease stages 3\u20135. Clin Nephrol. 2008;70:296\u2013305.","journal-title":"Clin Nephrol"},{"key":"491_CR37","doi-asserted-by":"crossref","unstructured":"Sprague SM, Bellorin-Font E, Jorgetti V, et al. Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis. 2015.","DOI":"10.1053\/j.ajkd.2015.06.023"},{"key":"491_CR38","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/jbmr.5650020617","volume":"2","author":"AM Parfitt","year":"1987","unstructured":"Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987;2:595\u2013610.","journal-title":"J Bone Miner Res"},{"key":"491_CR39","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/sj.ki.5000311","volume":"69","author":"FC Barreto","year":"2006","unstructured":"Barreto FC, Barreto DV, Moyses RM, et al. Osteoporosis in hemodialysis patients revisited by bone histomorphometry: a new insight into an old problem. Kidney Int. 2006;69:1852\u20137.","journal-title":"Kidney Int"},{"key":"491_CR40","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/ndt\/gfr317","volume":"27","author":"S Iimori","year":"2012","unstructured":"Iimori S, Mori Y, Akita W, et al. Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients--a single-center cohort study. Nephrol Dial Transplant. 2012;27:345\u201351.","journal-title":"Nephrol Dial Transplant"},{"key":"491_CR41","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.2215\/CJN.12871211","volume":"7","author":"RH Yenchek","year":"2012","unstructured":"\u2022\u2022 Yenchek RH, Ix JH, Shlipak MG, et al. Bone mineral density and fracture risk in older individuals with CKD. Clin J Am Soc Nephrol. 2012;7:1130\u20136 This was the first study to demonstrate that measurement of BMD by DXA predicted fracture in CKD patients with similar accuracy to that of patients with healthy kidney function.","journal-title":"Clin J Am Soc Nephrol."},{"key":"491_CR42","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/jbmr.2406","volume":"30","author":"SL West","year":"2015","unstructured":"West SL, Lok CE, Langsetmo L, et al. Bone mineral density predicts fractures in chronic kidney disease. J Bone Miner Res. 2015;30:913\u20139.","journal-title":"J Bone Miner Res"},{"key":"491_CR43","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","volume":"92","author":"M Ketteler","year":"2017","unstructured":"Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO chronic kidney disease\u2013mineral and bone disorder (CKD-MBD) guideline update: what\u2019s changed and why it matters. Kidney Int. 2017;92:26\u201336.","journal-title":"Kidney Int"},{"key":"491_CR44","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s11914-015-0262-3","volume":"13","author":"SA Jamal","year":"2015","unstructured":"Jamal SA, Nickolas TL. Bone imaging and fracture risk assessment in kidney disease. Current osteoporosis reports. 2015;13:166\u201372.","journal-title":"Current osteoporosis reports"},{"key":"491_CR45","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1681\/ASN.2010121275","volume":"22","author":"TL Nickolas","year":"2011","unstructured":"Nickolas TL, Cremers S, Zhang A, et al. Discriminants of prevalent fractures in chronic kidney disease. J Am Soc Nephrol. 2011;22:1560\u201372.","journal-title":"J Am Soc Nephrol"},{"key":"491_CR46","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","volume":"92","author":"M Ketteler","year":"2017","unstructured":"Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what\u2019s changed and why it matters. Kidney Int. 2017;92:26\u201336.","journal-title":"Kidney Int"},{"key":"491_CR47","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1053\/j.ajkd.2005.10.007","volume":"47","author":"D Coyne","year":"2006","unstructured":"Coyne D, Acharya M, Qiu P, et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis. 2006;47:263\u201376.","journal-title":"Am J Kidney Dis"},{"key":"491_CR48","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.2215\/CJN.10661013","volume":"9","author":"DW Coyne","year":"2014","unstructured":"Coyne DW, Goldberg S, Faber M, Ghossein C, Sprague SM. A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD. Clin J Am Soc Nephrol. 2014;9:1620\u20136.","journal-title":"Clin J Am Soc Nephrol"},{"key":"491_CR49","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","volume":"63","author":"SM Sprague","year":"2003","unstructured":"Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003;63:1483\u201390.","journal-title":"Kidney Int"},{"key":"491_CR50","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1111\/j.1523-1755.2005.00603.x","volume":"68","author":"G Coen","year":"2005","unstructured":"Coen G, Mantella D, Manni M, et al. 25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy. Kidney Int. 2005;68:1840\u20138.","journal-title":"Kidney Int"},{"key":"491_CR51","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s10157-012-0665-8","volume":"17","author":"Y Tsuruta","year":"2013","unstructured":"Tsuruta Y, Okano K, Kikuchi K, Tsuruta Y, Akiba T, Nitta K. Effects of cinacalcet on bone mineral density and bone markers in hemodialysis patients with secondary hyperparathyroidism. Clin Exp Nephrol. 2013;17:120\u20136.","journal-title":"Clin Exp Nephrol"},{"key":"491_CR52","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/ki.2014.349","volume":"87","author":"GJ Behets","year":"2015","unstructured":"Behets GJ, Spasovski G, Sterling LR, et al. Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism. Kidney Int. 2015;87:846\u201356.","journal-title":"Kidney Int"},{"key":"491_CR53","doi-asserted-by":"crossref","unstructured":"Moe SM, Abdalla S, Chertow GM, et al. Effects of cinacalcet on fracture events in patients receiving hemodialysis: the EVOLVE trial. J Am Soc Nephrol. 2014.","DOI":"10.1681\/ASN.2014040414"},{"key":"491_CR54","doi-asserted-by":"crossref","unstructured":"Ballinger AE, Palmer SC, Nistor I, Craig JC, Strippoli GF. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database Syst Rev. 2014:Cd006254.","DOI":"10.1002\/14651858.CD006254.pub2"},{"key":"491_CR55","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1001\/jama.2016.19468","volume":"317","author":"GA Block","year":"2017","unstructured":"Block GA, Bushinsky DA, Cheng S, et al. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. JAMA. 2017;317:156\u201364.","journal-title":"JAMA"},{"key":"491_CR56","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1001\/jama.2009.1462","volume":"302","author":"CA Brauer","year":"2009","unstructured":"Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB. Incidence and mortality of hip fractures in the United States. JAMA. 2009;302:1573\u20139.","journal-title":"JAMA"},{"key":"491_CR57","doi-asserted-by":"publisher","first-page":"649","DOI":"10.7326\/M16-2752","volume":"166","author":"LM Wilson","year":"2017","unstructured":"Wilson LM, Rebholz CM, Jirru E, et al. Benefits and harms of osteoporosis medications in patients with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2017;166:649\u201358.","journal-title":"Ann Intern Med"},{"key":"491_CR58","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1172\/JCI119668","volume":"100","author":"PM Chavassieux","year":"1997","unstructured":"Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest. 1997;100:1475\u201380.","journal-title":"J Clin Invest"},{"key":"491_CR59","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1359\/jbmr.070906","volume":"23","author":"RR Recker","year":"2008","unstructured":"Recker RR, Delmas PD, Halse J, et al. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res OffJ Am Soc Bone Miner Res. 2008;23:6\u201316.","journal-title":"J Bone Miner Res OffJ Am Soc Bone Miner Res."},{"key":"491_CR60","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1359\/JBMR.050817","volume":"20","author":"PD Miller","year":"2005","unstructured":"Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the cockcroft and gault method: a pooled analysis of nine clinical trials. J Bone Miner Res. 2005;20:2105\u201315.","journal-title":"J Bone Miner Res"},{"key":"491_CR61","doi-asserted-by":"crossref","unstructured":"Jamal SA, Bauer DC, Ensrud KE, et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial*. J Bone Miner Res. 2007.","DOI":"10.1359\/jbmr.070112"},{"key":"491_CR62","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1359\/JBMR.050817","volume":"20","author":"PD Miller","year":"2005","unstructured":"Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res Off J Am Soc Bone Miner Res. 2005;20:2105\u201315.","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res."},{"key":"491_CR63","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12882-017-0478-9","volume":"18","author":"T Shigematsu","year":"2017","unstructured":"Shigematsu T, Muraoka R, Sugimoto T, Nishizawa Y. Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials. BMC Nephrol. 2017;18:66.","journal-title":"BMC Nephrol"},{"key":"491_CR64","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1053\/j.ajkd.2009.12.039","volume":"56","author":"ND Toussaint","year":"2010","unstructured":"Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG. Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis. 2010;56:57\u201368.","journal-title":"Am J Kidney Dis"},{"key":"491_CR65","first-page":"510","volume":"21","author":"R Bergner","year":"2008","unstructured":"Bergner R, Henrich D, Hoffmann M, Schmidt-Gayk H, Lenz T, Upperkamp M. Treatment of reduced bone density with ibandronate in dialysis patients. J Nephrol. 2008;21:510\u20136.","journal-title":"J Nephrol."},{"key":"491_CR66","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s00198-016-3861-7","volume":"28","author":"M Ota","year":"2017","unstructured":"Ota M, Takahata M, Shimizu T, et al. Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia. Osteoporos Int. 2017;28:1481\u201390.","journal-title":"Osteoporos Int."},{"key":"491_CR67","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/jbmr.403","volume":"26","author":"SA Jamal","year":"2011","unstructured":"Jamal SA, Ljunggren O, Stehman-Breen C, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011;26:1829\u201335.","journal-title":"J Bone Miner Res"},{"key":"491_CR68","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756\u201365.","journal-title":"N Engl J Med"},{"issue":"7","key":"491_CR69","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1210\/jc.2014-1154","volume":"99","author":"Chien-Liang Chen","year":"2014","unstructured":"Chen CL, Chen NC, Hsu CY, et al. An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis. J Clin Endocrinol Metab. 2014;99(7):2426\u201332.","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"key":"491_CR70","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/jbmr.1613","volume":"27","author":"GA Block","year":"2012","unstructured":"Block GA, Bone HG, Fang L, Lee E, Padhi D. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res. 2012;27:1471\u20139.","journal-title":"J Bone Miner Res"},{"key":"491_CR71","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1053\/j.ajkd.2012.06.019","volume":"60","author":"BB McCormick","year":"2012","unstructured":"McCormick BB, Davis J, Burns KD. Severe hypocalcemia following denosumab injection in a hemodialysis patient. Am J Kidney Dis. 2012;60:626\u20138.","journal-title":"Am J Kidney Dis"},{"key":"491_CR72","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.amjms.2017.09.008","volume":"355","author":"SA Salim","year":"2018","unstructured":"Salim SA, Nair LR, Thomas L, et al. Denosumab-associated severe hypocalcemia in a patient with chronic kidney disease. Am J Med Sci. 2018;355:506\u20139.","journal-title":"Am J Med Sci"},{"key":"491_CR73","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40620-016-0334-1","volume":"30","author":"F Festuccia","year":"2017","unstructured":"Festuccia F, Jafari MT, Moioli A, et al. Safety and efficacy of denosumab in osteoporotic hemodialysed patients. J Nephrol. 2017;30:271\u20139.","journal-title":"J Nephrol."},{"key":"491_CR74","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/S0140-6736(97)02342-8","volume":"350","author":"R Lindsay","year":"1997","unstructured":"Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet. 1997;350:550\u20135.","journal-title":"Lancet"},{"key":"491_CR75","doi-asserted-by":"publisher","first-page":"4208","DOI":"10.1210\/jc.2015-2829","volume":"100","author":"A Cohen","year":"2015","unstructured":"Cohen A, Kamanda-Kosseh M, Recker RR, et al. Bone density after teriparatide discontinuation in premenopausal idiopathic osteoporosis. J Clin Endocrinol Metab. 2015;100:4208\u201314.","journal-title":"J Clin Endocrinol Metab"},{"key":"491_CR76","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434\u201341.","journal-title":"N Engl J Med"},{"key":"491_CR77","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1056\/NEJMoa071408","volume":"357","author":"KG Saag","year":"2007","unstructured":"Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357:2028\u201339.","journal-title":"N Engl J Med"},{"key":"491_CR78","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1359\/jbmr.2003.18.11.1932","volume":"18","author":"Y Jiang","year":"2003","unstructured":"Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res Off J Am Soc Bone Miner Res. 2003;18:1932\u201341.","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res."},{"key":"491_CR79","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1359\/jbmr.070413","volume":"22","author":"P Chen","year":"2007","unstructured":"Chen P, Miller PD, Recker R, et al. Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. J Bone Miner Res Off J Am Soc Bone Miner Res. 2007;22:1173\u201380.","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res."},{"key":"491_CR80","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00198-006-0189-8","volume":"18","author":"PD Miller","year":"2007","unstructured":"Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int. 2007;18:59\u201368.","journal-title":"Osteoporos Int"},{"key":"491_CR81","doi-asserted-by":"publisher","first-page":"166","DOI":"10.5414\/CP202001","volume":"52","author":"H Imai","year":"2014","unstructured":"Imai H, Watanabe M, Fujita T, Watanabe H, Harada K, Moritoyo T. Pharmacokinetics of teriparatide after subcutaneous administration to volunteers with renal failure: a pilot study. Int J Clin Pharmacol Ther. 2014;52:166\u201374.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"491_CR82","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1681\/ASN.2007050555","volume":"19","author":"A Ishani","year":"2008","unstructured":"Ishani A, Blackwell T, Jamal SA, Cummings SR, Ensrud KE, Investigators M. The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol. 2008;19:1430\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"491_CR83","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1111\/j.1600-6143.2008.02327.x","volume":"8","author":"D Cejka","year":"2008","unstructured":"Cejka D, Benesch T, Krestan C, et al. Effect of teriparatide on early bone loss after kidney transplantation. Am J Transplant. 2008;8:1864\u201370.","journal-title":"Am J Transplant"},{"key":"491_CR84","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000316708","volume":"33","author":"D Cejka","year":"2010","unstructured":"Cejka D, Kodras K, Bader T, Haas M. Treatment of hemodialysis-associated adynamic bone disease with teriparatide (PTH1-34): a pilot study. Kidney Blood Press Res. 2010;33:221\u20136.","journal-title":"Kidney Blood Press Res."},{"key":"491_CR85","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1053\/j.ajkd.2015.01.025","volume":"65","author":"P Palcu","year":"2015","unstructured":"Palcu P, Dion N, Ste-Marie LG, et al. Teriparatide and bone turnover and formation in a hemodialysis patient with low-turnover bone disease: a case report. Am J Kidney Dis. 2015;65:933\u20136.","journal-title":"Am J Kidney Dis"},{"key":"491_CR86","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/s00198-015-3377-6","volume":"27","author":"K Sumida","year":"2016","unstructured":"Sumida K, Ubara Y, Hoshino J, et al. Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study. Osteoporos Int. 2016;27:1441\u201350.","journal-title":"Osteoporos Int"},{"key":"491_CR87","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/s00198-015-3377-6","volume":"27","author":"K Sumida","year":"2016","unstructured":"Sumida K, Ubara Y, Hoshino J, et al. Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study. Osteoporos Int. 2016;27:1441\u201350.","journal-title":"Osteoporos Int"},{"key":"491_CR88","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1210\/en.2015-1726","volume":"157","author":"G Hattersley","year":"2016","unstructured":"Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ. Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling. Endocrinology. 2016;157:141\u20139.","journal-title":"Endocrinology"},{"key":"491_CR89","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00223-016-0171-1","volume":"99","author":"H Bahar","year":"2016","unstructured":"Bahar H, Gallacher K, Downall J, Nelson CA, Shomali M, Hattersley G. Six weeks of daily abaloparatide treatment increased vertebral and femoral bone mineral density, microarchitecture and strength in ovariectomized osteopenic rats. Calcif Tissue Int. 2016;99:489\u201399.","journal-title":"Calcif Tissue Int"},{"key":"491_CR90","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/jbmr.3003","volume":"32","author":"A Varela","year":"2017","unstructured":"Varela A, Chouinard L, Lesage E, Smith SY, Hattersley G. One year of abaloparatide, a selective activator of the PTH1 receptor, increased bone formation and bone mass in osteopenic ovariectomized rats without increasing bone resorption. J Bone Miner Res. 2017;32:24\u201333.","journal-title":"J Bone Miner Res"},{"key":"491_CR91","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00198-017-4323-6","volume":"29","author":"N Doyle","year":"2018","unstructured":"Doyle N, Varela A, Haile S, et al. Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption. Osteoporos Int. 2018;29:685\u201397.","journal-title":"Osteoporos Int"},{"key":"491_CR92","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1210\/jc.2014-3718","volume":"100","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, O'Dea LS, Zanchetta JR, et al. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2015;100:697\u2013706.","journal-title":"J Clin Endocrinol Metab"},{"key":"491_CR93","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016;316:722\u201333.","journal-title":"JAMA"},{"key":"491_CR94","doi-asserted-by":"crossref","unstructured":"Moreira C, Fitzpatrick LA, Wang Y, Recker RR. Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone. 2016.","DOI":"10.1016\/j.bone.2016.11.004"},{"key":"491_CR95","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s00223-016-0161-3","volume":"99","author":"G Adami","year":"2016","unstructured":"Adami G, Orsolini G, Adami S, et al. Effects of TNF inhibitors on parathyroid hormone and Wnt signaling antagonists in rheumatoid arthritis. Calcif Tissue Int. 2016;99:360\u20134.","journal-title":"Calcif Tissue Int"},{"key":"491_CR96","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jbspin.2014.10.015","volume":"82","author":"K Briot","year":"2015","unstructured":"Briot K, Rouanet S, Schaeverbeke T, et al. The effect of tocilizumab on bone mineral density, serum levels of Dickkopf-1 and bone remodeling markers in patients with rheumatoid arthritis. Joint, bone, spine : revue du rhumatisme. 2015;82:109\u201315.","journal-title":"Joint, bone, spine : revue du rhumatisme"},{"key":"491_CR97","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370:412\u201320.","journal-title":"N Engl J Med"},{"key":"491_CR98","doi-asserted-by":"crossref","unstructured":"Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017.","DOI":"10.1056\/NEJMoa1708322"},{"key":"491_CR99","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375:1532\u201343.","journal-title":"N Engl J Med"},{"key":"491_CR100","doi-asserted-by":"crossref","unstructured":"Langdahl BL, Libanati C, Crittenden DB, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. 2017.","DOI":"10.1016\/S0140-6736(17)31613-6"},{"key":"491_CR101","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/jbmr.212","volume":"26","author":"JA Eisman","year":"2011","unstructured":"Eisman JA, Bone HG, Hosking DJ, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res. 2011;26:242\u201351.","journal-title":"J Bone Miner Res"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11914-018-0491-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-018-0491-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-018-0491-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T13:34:57Z","timestamp":1650116097000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11914-018-0491-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,23]]},"references-count":101,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["491"],"URL":"https:\/\/doi.org\/10.1007\/s11914-018-0491-3","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,23]]},"assertion":[{"value":"23 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Thomas Nickolas reports grant support and person fees from Amgen and is on the Scientific Advisory Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}